Rush to End Drug Rebates May Be Bad for Patients, Payers, and Pharma

In health care circles, 21 words have rarely caused as much speculation as “Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection,” the title of proposed regulations currently under review at the Office of Management and Budget.

Stat

Published On

September 7, 2018

Author

National Advisor

Ian Spatz

San Francisco

310.312.4339

Rush to End Drug Rebates May Be Bad for Patients, Payers, and Pharma

In health care circles, 21 words have rarely caused as much speculation as “Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection,” the title of proposed regulations currently under review at the Office of Management and Budget.

Stat

Join our newsletter to stay up to date on features and releases.

ATTORNEY ADVERTISING, pursuant to New York DR 2-101(f)

© 2025 Manatt, Phelps & Phillips, LLP. All rights reserved.

Newsletter Subscription